|Articles|May 1, 2002
Decision reversed: Medicare will not pay for OPT in occult wet AMD
Washington, DC-Citing concerns about safety and long-term benefits, the U.S. Centers for Medicare and Medicaid Services (CMS) has reversed its October 2001 decision to reimburse patients who receive ocular photodynamic therapy (PCT)
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5


















